<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102641">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02075060</url>
  </required_header>
  <id_info>
    <org_study_id>IPOI vs IPOP</org_study_id>
    <nct_id>NCT02075060</nct_id>
  </id_info>
  <brief_title>Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <authority>France : ANSM - French Health Products Safety Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to assess the efficacy and toxicity of immediate
      pre-operative instillation of mitomycin C compared to the standard early post-operative .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Non Muscle-invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>IPOI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One arm with pre-operative instillation 1h before TURB (IPOI : Instillation pré-opératoire immédiate),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One arm with early post-operative instillation within 24 hours (IPOP : Instillation Post Opératoire Précoce).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IPOI (pre-operative)</intervention_name>
    <arm_group_label>IPOI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IPOP (post-operative)</intervention_name>
    <arm_group_label>IPOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years,

          -  Primary or recurrent bladder tumor with endoscopic papillary aspect,

          -  One or two bladder tumors,

          -  Cytology before TURB showing no high-grade cells,

          -  Patients without tutorship or subordination (ou curatorship),

          -  Patients under the general social security system or qualifying through a third
             party,

          -  Informed consent signed by the patient after clear and fair information.

        Exclusion Criteria:

          -  Age &lt; 18 years,

          -  Allergy to mitomycin C,

          -  Traumatic stenting,

          -  Upper tract urothelial cancer,

          -  Urethral invasion,

          -  History of muscle invasive bladder cancer,

          -  Extensive tumor (3 cm or more),

          -  Any contraindication to TURB,

          -  Simultaneous participation in another clinical research study,

          -  Patients not insured by the social security or not qualifying through a third party,

          -  Patients with enhanced protection, namely pregnant or lactating women, persons
             deprived of their liberty by a judicial or administrative decision, people staying in
             a health or social institution, adults under legal protection, and finally patients
             in emergency situations,

          -  Pregnant or lactating females or women of childbearing potential not willing to use
             an adequate method of birth control for the duration of the study (i.e. hormonal /
             mechanical contraceptive : oral, injectable, transdermal, implantable, intrauterine
             or surgical device: tubal ligation, hysterectomy, total oophorectomy).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacques IRANI, MD, PhD</last_name>
    <phone>: +33 (0)5.49.44.44.77</phone>
    <email>jacques.irani@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Poitiers University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques IRANI, MD, PhD</last_name>
      <phone>+33 (0)5.49.44.44.77</phone>
      <email>jacques.irani@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques IRANI, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>February 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>low-grade</keyword>
  <keyword>NMIBC</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
